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Telomere lengthDown Syndrome is the most common chromosomal disease and is also known for its decreased incidence of solid
tumors and its progeroid phenotype. Cellular and systemic oxidative stress has been considered as one of the
Down Syndrome phenotype causes.We correlated, in a preliminary study, the ﬁbroblast proliferation rate and dif-
ferent cell proliferation key regulators, like Rcan1 and the telomere length from Down Syndrome fetuses, with
their oxidative stress proﬁle and the Ribonucleic acid and protein expression of the main antioxidant enzymes to-
gether with their activity. Increased oxidized glutathione/glutathione ratio and high peroxide production were
found in our cell model. These results correlated with a distorted antioxidant shield. The messenger RNA (SOD1)
and protein levels of copper/zinc superoxide dismutase were increased together with a decreased mRNA expres-
sion and protein levels of glutathione peroxidase (GPx). As a consequence the [Cu/ZnSOD / (catalase + GPx)] ac-
tivity ratio increases which explains the oxidative stress generated in the cell model. In addition, the expression of
thioredoxin 1 and glutaredoxin 1 is decreased. The results obtained show a decreased antioxidant phenotype that
correlates with increased levels of Regulator of calcineurin 1 and attrition of telomeres, both related to oxidative
stress and cell cycle impairment. Our preliminary results may explain the proneness to a progeroid phenotype.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Down Syndrome (DS) is the most common chromosomal disease
and one of themain causes of intellectual disability. The genes localized
in chromosome 21 are linked tomitochondrial energy production, reac-
tive oxygen species metabolism, brain development, neuronal loss, and
Alzheimer's type neurodegeneration [1]. Another interesting feature is
that individuals with DS have a reduced risk of solid tumors in all the
age groups studied [2] and a progeria-like phenotype [3].
The presence of an oxidative stress status in DS patients has beenwell
established [4–8]. The source of the systemic oxidative stress found insuperoxide dismutase;MnSOD,
, telomere length; ROS, reactive
ldehyde-3-phosphate dehydro-
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ights reserved.DS individuals is not clear, although it is known that Cu/Zn superoxide
dismutase (Cu/ZnSOD) activity is increased in DS patients [9] and the
ratio Cu/ZnSOD to catalase plus glutathione peroxidase [Cu/ZnSOD /
(catalase + glutathione peroxidase)] is increased [10]. The activity of
the selenoenzymeGPx could be hampered by the reported lack of seleni-
um levels observed inDS [11]. Thusmore hydrogenperoxide is generated
by Cu/ZnSOD than catalase and glutathione peroxidase can catabolize,
giving rise to an oxidative stress positive feed-back [12]. This process
generates a positive feed-back inducing mitochondrial dysfunction [13]
and impairing the respiratory complex enzymes [14], which in turn
would keep increasing ROS production.
It was reported that cells from DS, or animal model of DS are
prone to oxidative stress and apoptosis and have lower proliferation
capability [15–19]. This ﬁnding could explain, at least in part, some of
the progeria-like characteristics of the DS phenotype. Previous reports
from our group have emphasized the importance of glutathione (GSH)
in cell proliferation [20–22].
The purpose of our study was to clarify the cause of the progeroid-
like phenotype and the reported impairment in cell proliferation. Here
we provide new information showing that the high oxidative stress
previously reported in DS is a very early event in development that is
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ly in amnioticﬂuid formwomen carryingDS fetuses [23] and in brain fe-
tuses [24,25]. In addition, our ﬁndings show a decreased antioxidant
shield and an increased production of free radicals. These results partial-
ly explain the attrition of the telomere and the increased expression of
Rcan1.
2. Material and methods
2.1. Human dermal ﬁbroblast cultures from Down Syndrome (DS) and
control (C) fetuses
Abdominal skin biopsies from six human fetuses, products of legal
terminations, were collected with informed parental consent and ap-
proved by the Ethics Committee of theHospital, within 2 h postmortem
from the Fetal Tissue Bank at the Hospital Universitari Vall d'Hebron
(fetaltissuepath@vhebron.net). Three fetuses were diagnosed as having
Down Syndrome (DS): one 47, XY + 21, gestational age (GA) 20 weeks
(w); one 47, XY + 21, GA16 weeks; and one 47, XY + 21, t(21;21), GA
22 weeks. Three fetuseswere considered as controls (C): one 46, XX, GA
22 weeks, diagnosed with complex cardiac malformation; one 46, XY,
GA 22 weeks, diagnosed with anhydramnios with previous membrane
rupture and the absence of congenital anomalies; and one 46, XX, GA
14 weeks, diagnosed with occipital encephalocele.
Primary ﬁbroblasts were obtained from skin explants in a 25-cm2
plastic cultureﬂaskwith Eagle'sMinimal EssentialMedium(MEM) sup-
plemented with nonessential amino acids, 10% fetal calf serum (FCS)
and antibiotics (100 IU/ml penicillin and 100 mg/ml streptomycin).
The ﬂasks were maintained at 37 °C in a 95% humidiﬁed air–5% CO2
atmosphere. The ﬁbroblasts were released by enzymatic digestion with
trypsin and sub-cultured in a 75-cm2 plastic culture ﬂask with 12 ml of
medium. The cultures were fed by changing the medium every three
days. After reaching conﬂuence, the cells were washed and the pellet
resuspended in 1 ml of MEM with 10% FCS and DMSO and frozen
(24 h at −80 °C and then in liquid nitrogen). The cells were thawed
and reincorporated into the cultures for ensuing experiments.
The cells were subsequently cultured in DMEM (Gibco,
Invitrogen) supplemented with 10% fetal bovine serum and 1%
penicillin–streptomycin (Sigma-Aldrich, MO, USA) in 5% CO2 in air
at 37 °C at a density of 20.000 cells/cm2. The sub-cultured method
used was digestion with trypsin. All experiments were performed
with the same number of passages: 8–10. Studies were performed
at different time points in cell culture.
2.2. Analysis of apoptotic cells by ﬂow cytometry
Quantitative analysis of apoptotic cell death was performed by
ﬂow cytometry using Annexin V-Alexa Fluor 488 conjugate (Molecular
Probes, OR, USA). Cells from culture supernatant and adherent cells
collected after trypsinization, were stained with the reactive following
the manufacturer's instructions, and 1 μg/ml of propidium iodide (PI)
staining at room temperature for 15 min in the dark, followed by cyto-
metric analysis in anEpics Elite cell sorter (Coulter Electronics, LA, USA).
Fluorescence emissions were recorded at 515 ± 10 nm.
2.3. Cellular proliferation assay
Proliferation of DS and control ﬁbroblasts was determined with the
“Cell proliferation ELISA BdrU colorimetric” (Roche, NY, USA) as per
the manufacturer's recommendations. The cells were cultured in a 96
well plate for 6 h, 24 h, 48 h, and 7 days. The colorimetric ﬁnal reaction
was measured with the spectrophotometer spectra MAXPLUS 384
(Molecular Devices, USA) at 370 nm using as reference wavelength
492 nm, during three consecutive ﬁve-minute periods. The variation
of absorbance was proportional to the incorporation of BdrU.2.4. Telomere length (TL)
DNA was extracted from approximately 5 · 105 cells using the
DNeasy Blood and Tissue Handbook (Quiagen), and then quantiﬁed
using the GeneQuant pro UV/Vis (GE Healthcare, Uppsala, Sweden).
TL average in ﬁbroblasts was measured with a validated quantitative
(Q-PCR) based assay [26,27]. This method measures the average
ratio of the telomere repeat copy numbers to a single gene (36B4)
copy numbers (T/S ratio) in each sample. All samples weremeasured
in duplicate, and their mean was used. Each of the experiments was
performed in triplicate.
Brieﬂy, the Q-PCR technique was performed using a LightCycler
thermocycler (LightCycler 480II, Roche Diagnostics, Quebec, Canada)
in a 384-well format. Duplicate DNA sampleswere ampliﬁed in parallel:
20 μl PCR reactions included 30 ng of sample DNA, the DNA master
SYBR Green I kit (LightCycler® 480 Sybr Green I Master, Roche Diag-
nostics, USA) and 0.5 pmol/ml of speciﬁc primers for the telomere
(forward: 5′CGGTTTGTTTGGGTTTGGGTTTGGGTTTGGGTTTGGGTT3′;
reverse 5′GGCTTGCCTTACCCTTACCCTTACCCTTACCCTTACCCT3′) and
for the 36B4 (forward: 5′CAGCAAGTGGGAAGGTGTAATCC3′; reverse:
5′CCCATTCTATCATCAACGGGTACAA3′). The thermal cycling proﬁle
for both amplicons began with a cycle at 95 °C for 15 min, followed
by 35 cycles at 95 °C for 30 s, 55 °C for 1 min and 72 °C for 10 s. The
speciﬁcity of all reactions was determined by melting point curve anal-
ysis using one cycle at 95 °C for 5 s, 70 °C for 1 min, and one cycle at
40 °C for 30 s.
The technique was optimized by developing standard curves using
serial dilutions from a reference DNA. This methodmeasures the average
ratio of telomere repeat copy number to a single gene (36B4) copy num-
ber (T/S ratio) in each sample.
The linear correlation coefﬁcient (r2) was N0.99 for the telomeric
and 36B4 standard curves. The efﬁciency of the ampliﬁcation was
calculated from the slope of the linear curves. The average efﬁciency
was 2.048 for telomeric ampliﬁcation and 1.98 for 36B4 ampliﬁca-
tion. The T/S ratio was calculated using these efﬁciency values: T/S
ratio = efﬁciencyCp 36B4/efﬁciencyCpTel. The coefﬁcients of variation
(CV) within duplicates of the telomere length and 36B4 assays were
2.4% and 0.9%, respectively.
2.5. Peroxide levels: ﬂow cytometry analysis
Acute intracellular production of reactive oxygen species (ROS) was
assessed by incubation (30 min) of cell aliquots with dihydrorhodamine
(DHR), 0.7 μM. These virtually non-ﬂuorescent probes are oxidized to a
ﬂuorescent product. Fluorescence of a single cell was measured by a
ﬂow cytometer, Epics Elite cell sorter (Coulter Electronics, LA, USA). Fluo-
rochromewas excitedwith an argon laser tuned at 488 nmand emission
at 515 ± 10 nm. Forward angle and right angle light scattering were
measured. Samples were acquired for 15,000 individual cells and ROS
production was quantiﬁed by mean ﬂuorescence intensities.
2.6. Determination of the GSSG/GSH ratio
The GSSG and GSH concentration was measured using DetectX®
Glutathione Fluorescent Detection Kit (Arbors Assay, MI, USA) and the
GSSG/GSH ratio was calculated. The cells were grown to conﬂuence in
seven days. The washed cell pellet was resuspended in 5% sulfosalicylic
acid (w/v), at 106 cells/ml, and was lysed and deproteinized by two
freeze/thaw cycles in liquid nitrogen. The measurements were per-
formed following themanufacturer's instructions. Theﬂuorescent prod-
uct was read at 510 nm with excitation at 390 nm in the ﬂuorometer
spectra MAX GEMINIS (Molecular Devices, Sunnyvale, USA). Subse-
quently, we incubated the plate with NADPH and glutathione reductase
to convert all oxidized glutathione, GSSG, into GSH, which reacts with
the excess ThioStar® to yield the signal related to total GSH content.
GSSG was calculated as GSSG = [(GSHtotal − GSHfree) / 2].
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quantitative PCR
Total RNAwas isolated from cells using the PARIS™ Protein and RNA
Isolation System (Ambion, TX, USA) following the manufacturer's
instructions. 1 μg of the puriﬁed RNA was reverse transcribed using
random hexamers with the High-Capacity cDNA Archive kit (Applied
Biosystems, P/N: 4322171, CA, USA) according to themanufacturer's in-
structions. ThemRNA levels were determined by quantitative real-time
PCR analysis using an ABI Prism 7900 HT Fast Real-Time PCR System
(Applied Biosystems, CA, USA).
TAqMan gene expression assays for SOD1, SOD2, CAT, GPX1, TXN1
and GRX1 (Assay-on-demand, Applied Biosystems) were used together
with 1× TaqMan® Universal PCR Master Mix (Applied Biosystems,
P/N 4304437; CA, USA) and 2 μl of reverse transcribed sample RNA
in 20 μl reaction volumes. The PCR conditions were 10 min at
95 °C for enzyme activation, followed by 40 two-step cycles (15 s at
95 °C; 1 min at 60 °C). The levels of glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) expression were measured in all samples to
normalize gene expression for sample-to-sample differences in RNA
input, RNA quality, and reverse transcription efﬁciency. Each sample
was analyzed in triplicate, and the expression was calculated according
to the 2−ΔΔCt method [28].
2.8. Cell lysates and Western blot analysis
Approximately 3 · 106 cells were lysed using lysis buffer (20 mM
Hepes, pH 7.4, 1% tritonX-100, 100 mM NaCl, 50 mM NaF, 10 mMFig. 1. Cell proliferation, telomere length (TL) and oxidative stress proﬁle for Down Syndrom
time-points and then incubated with BrdU for 3 h. BrdU incorporation was determined using
mean ± SD. Each experiment was repeated twice, n = 6. Statistically signiﬁcant differences (
are shown as individual values and mean ± SD; the number of determinations is stated in br
ratio was calculated using the efﬁciency of the ampliﬁcation values: T/S ratio = efﬁciency
control average. (C) Cellular levels of peroxideweremeasured byﬂow cytometry detection 48 h
are mean ± SD of three different experiments with three different DS patients and three diff
detection kit, graph bars showmean ± SD of a total of three experiments. Statistically signiﬁcβ-glycerophosphate, 1 mM activated sodium orthovanadate, 1 mM
PMSF, 0.2 % (v/v) protein proteases inhibitor cocktail), in ice for about
15 min and then the suspension was clariﬁed by centrifugation and
the supernatants were collected and stored at −80 °C until their use.
Total cell extracts were obtained in the absence of reductive agents.
Protein content was determined by a modiﬁed Lowry method [29].
Aliquots of cell lysates (30–40 μg) were added to sample buffer with
10% β-mercaptoethanol and fractionated by sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE). The proteins were
electroblotted (Bio-Rad) onto nitrocellulose membrane. Membranes
were incubated with primary antibodies that recognize MnSOD
(1:1000, Stressgen, Ann Arbor, MI, USA), Cu/ZnSOD (1:1000, Stressgen,
AnnArbor,MI, USA), catalase (1:5000, Sigma-Aldrich), GPx1 (1.5 μg/ml,
Abcam, Cambridge, MA, USA), Trx1 (1:1000, Cell Signaling Technology,
Inc. MA, USA), Grx1 (1:1000, Abcam, Cambridge, MA, USA), Rcan1 (anti
DSCR1), a synthetic peptide corresponding to amino acids 235–252 of
human DSCR1 (Gene ID 1827) (1:500 Sigma-Aldrich), and α-tubulin
(1:1000, Santa Cruz BioTech.) as a loading control, overnight at 4 °C.
The blots were incubated for 1 h with a secondary antibody (mouse,
rabbit, or goat, according to the antibody) conjugated with horseradish
peroxidase-linked. Finally, detection was carried out using the ECL™
Western Blotting Detection Reagents as speciﬁed by the manufacturer
(Amersham GE Healthcare). Chemiluminescent signals were assessed
using a Fujiﬁlm scanning densitometer (Fujiﬁlm LAS-1000 plus).
Western blotting of total extract in non-reducing buffer and electro-
phoresis conditions were performed to determine glutathionylated
proteins, using 20 μg of total protein. The primary antibody used was
anti-glutathione antibody (1:1000, Virogen, Grater Boston, MA, USA).e (DS) and control ﬁbroblasts (C). (A) Cell proliferation: Cells were cultured at different
a BrdU antibody as described in the Material and methods section. The bar graph shows
p b 0.05) were compared with the control average. (B) TL of DS and C ﬁbroblasts: Results
ackets. Experiments were performed in triplicate (two DS values were outliers). The T/S
Cp 36B4/efﬁciencyCpTel. Statistically signiﬁcant differences (p b 0.05) compared with the
and 7 days after cell culture, as described in theMaterial andmethods section. The results
erent controls in each experiment. (D) GSSG/GSH cellular ratio evaluated by ﬂuorimetric
ant differences (p b 0.05) compared with the control average.
119A. Gimeno et al. / Biochimica et Biophysica Acta 1842 (2014) 116–125The level of protein oxidation was determined by the Oxy Blot pro-
tein Oxidation Detection Kit (Merck Millipore, MA, USA) which detects
carbonylated proteins. To determine oxidized protein carbonyl groups,
20 μg of total extracts was derivatized to 2,4-dinitrophenylhydrazone
(DNP-hydrazone) by reaction with 2,4-dinitrophenylhydrazine (DNPH).
The derivatized samples were separated by SDS-PAGE electrophoresis
followed by Western blotting and immunodetection protocols as previ-
ously described.
2.9. Measurement of antioxidant enzymatic activities
2.9.1. Measurement of Cu/ZnSOD and MnSOD activity
The cellswere treated as described by theCaymanChemical Company
“Superoxide Dismutase Assay kit” following the manufacturer's in-
structions (Ann Arbor, MI, USA) to determine total SOD, MnSOD,
and Cu/ZnSOD activities. The ﬁnal absorbance was measured at 450 nm
using a SPECTRA MAXPLUS 384 spectrophotometer (Molecular Devices,
CA, USA).
2.9.2. Measurement of catalase activity
Catalase enzymatic activity was determined bymeasuring the prod-
uct of the reaction of catalase in the cells with peroxide. Cells were lysed
using a freeze (liquid N2, 10 s) and thaw (ice, 15 min) procedure re-
peated three times. After centrifugation of the cell lysate at 13,000 g,
for 10 min at 4 °C, 98% methanol and 84 mM H2O2 were added.
The formaldehyde produced reacted with 35 mM purpald reagentFig. 2.Glutathionylated and oxidized total proteins for Down Syndrome (DS) and control cells. E
compared with the control average. (A) Glutathionylated total proteins in DS and control ﬁbr
representative experiment is shown. (B) Oxidized total proteins in DS and control ﬁbroblasts a
tative experiment is shown.(4-amino-3-hydrazino-5-mercapto-1,2,4-triazole) dissolved in 0.5 M
HCl for 10 min, at room temperature. Finally, the absorbance at wave-
length 540 nm was measured with a SPECTRA MAXPLUS 384 spectro-
photometer (Molecular Devices, CA, USA).
2.9.3. Measurement of glutathione peroxidase activity
To determinate GPx activity the cells were treated as described by
the manufacturer for “GPx Assay kit” (Cayman Chemical Company, MI,
USA). The rate of decrease in absorbance at 340 nm (1 mU/ml GPx)
wasmeasured by the SPECTRAMAXPLUS 384 spectrophotometer (Mo-
lecular Devices, CA, USA).
2.10. Statistical analyses
Results are expressed as mean ± standard deviation. A non-
parametric Mann–Whitney U test for independent samples was applied
to compare control and DS results. The null hypothesis considered the
lack of differences between the group means and was rejected for p
values b0.05. The statistical software used was IBM SPSS Statistics 20.0.0.
3. Results
3.1. Impairment of cell proliferation
Fetal ﬁbroblast proliferation from control samples determined by
bromodeoxyuridine (BrdU) showed a high rate of proliferation up toach experimentwas performed in triplicate. Statistically signiﬁcant differences (p b 0.05)
oblasts at different time points in culture (6 h, 24 h, 48 h, and 7 days). Western blot of a
t different time points in culture (6 h, 24 h, 48 h, and 7 days). Western blot of a represen-
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for the rest of the culture. However, proliferation of ﬁbroblasts from DS
fetuses was signiﬁcantly lower, mainly during the ﬁrst 24 h of culture
and remained lower until cells had been in culture for seven days (see
Fig. 1A). No changes in basal apoptosis were detected between DS and
control fetal ﬁbroblasts (results not shown).
3.2. Telomeric length in ﬁbroblasts from Down Syndrome fetuses
Telomere length is a well-knownmarker of cell proliferation and an
index of cellular senescence. Fig. 1B shows a consistent and statistically
signiﬁcant 15.16% attrition of telomeres in the fetal DS ﬁbroblast prima-
ry cell lines when compared with their control counterparts.
Thus, cells from DS have lower potential for proliferation than ﬁbro-
blasts from control fetuses in the early stages of human development.
3.3. Oxidative stress proﬁle in cells from Down Syndrome fetuses
Since previous reports have emphasized the role of Cu/ZnSOD in the
production of high hydrogen peroxide levels in cells from DS patients
and as a systemic oxidative stress has been previously reported by
different authors, a number of different parameters of oxidative stress
and antioxidants were determined in our cell model.
As expected, peroxide levels were signiﬁcantly higher in ﬁbroblasts
from DS fetuses (Fig. 1C), and were 38% higher 48 h after culture and
28.75% 7 days after plating. Thus a consistent and continuous oxidativeFig. 3. Analysis of thioredoxin 1 and glutaredoxin 1 in Down Syndrome (DS) and control ﬁbrob
termined by qRT-PCR (C) Trx1 protein levels analyzed byWestern blot, a representative experi
showmean ± SD of a total of three experiments. (D) Grx1 protein levels analyzed by Western
ferent experiments. Graph bars show mean ± SD of a total of three experiments. Statistically sstress took place throughout the cell culture. Similarly, we determined
the GSSG/GSH ratio as a measure of oxidative stress. In keeping
with peroxide levels, the GSSG/GSH ratio was signiﬁcantly higher
in ﬁbroblasts from DS fetuses (Fig. 1D). However, the independent
concentrations of GSH and GSSG did not show signiﬁcant differ-
ences between groups (results not shown). These results suggest
a clear oxidative stress during cell proliferation in ﬁbroblasts from
DS when compared with controls. Cellular proteins may become
prone to S-glutathionylation and protein carbonylation as a possible
consequence of this oxidative stress status. Indeed, Fig. 2A shows
increased protein glutathionylation 24 h, 48 h, and 7 days after
seeding. Protein carbonylation was also higher at day seven of cul-
ture (Fig. 2B).
3.4. Antioxidant defense in Down Syndrome ﬁbroblasts
In order to explain the reported oxidative status of DS fetus ﬁbro-
blasts, we determined a wide array of antioxidant cellular components.
Fig. 3A shows a consistent decrease in the expression of TXN1 gene, the
gene that codiﬁes in humans for thioredoxin 1 (Trx1) one of the main
members of the thioredoxin family. The thioredoxin family is one of
the major regulators of the thiol redox state. Thioredoxin is a general
protein disulﬁde reductase being an important component of the anti-
oxidant cellular shield that has not been studied previously in DS ﬁbro-
blasts. Expressionwas almost absentwhen comparedwith control cells,
after 48 h and 7 days in culture.lasts (C). (A)mRNA levels for TXN1 determined by qRT-PCR. (B) mRNA levels for GRX1 de-
ment, and quantiﬁcation ofWestern blot of Trx1of three different experiments. Graph bars
blot, a representative experiment, and quantiﬁcation of Western blot of Grx1 of three dif-
igniﬁcant differences (p b 0.05) compared with the control average.
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tathione as electron donor. However, GRX1mRNA expression (Fig. 3B)
was not signiﬁcantly different in either cell type. The protein expression
results of both antioxidant enzymes (Fig. 3C and D) conﬁrmed our RT-
PCR results. As occurred for the respective gene expression, thioredoxin
1 protein was lower in DS (mainly 48 h after culture). There was an
absence of a statistically signiﬁcant difference in glutaredoxin 1 protein
expression.
It was previously reported that Cu/ZnSOD activity was higher in DS
patients. As expected, we found higher SOD1 (the gene that codiﬁes
for Cu/ZnSOD) mRNA levels, in ﬁbroblasts from DS fetuses (Fig. 4A,
left). Expression of Cu/ZnSOD proteins was also higher after 48 h in cul-
ture (Fig. 4B and C), although the differences were not statistically sig-
niﬁcant. SOD2 (the gene that codiﬁes for MnSOD) mRNA levels were
signiﬁcantly lower in DS ﬁbroblasts seven days after culture (Fig. 4A,
right). However these results were not correlated with statistically sig-
niﬁcant changes in the levels of the MnSOD protein (Fig. 4B and C).Fig. 4. Analysis of superoxide detoxifying enzymes in Down Syndrome (DS) and control ﬁbrob
qRT-PCR (left). mRNA levels for SOD2 (the gene that codiﬁes for MnSOD), determined by qRT-P
tative experiment. (C) Quantiﬁcation of Western blot of Cu/ZnSOD (left) and MnSOD (right). G
ences (p b 0.05) compared with the control average.Since SOD actionmust be coordinated with catalase and glutathione
peroxidase (GPx) activity in order to metabolize the H2O2 produced by
SOD enzymes, we focused our attention on these H2O2 antioxidant
enzymes. The results presented in Fig. 5A and B showed no changes
in CAT mRNA and catalase protein levels. However a signiﬁcant dec-
rement, more than a 50% decrease, in mRNA and protein expression
was found for GPx in cell extracts fromDS fetal ﬁbroblasts. In order to
obtain a complete picture of the antioxidant imbalance in the antiox-
idant enzymes, we determined the enzymatic activity of Cu/ZnSOD,
MnSOD, catalase, and GPx. These results showed a signiﬁcant increase
in Cu/ZnSOD (Fig. 6A) and a decrease in GPx activity (Fig. 6D), with
non-signiﬁcant changes in MnSOD (Fig. 6B) and catalase activity
(Fig. 6C).
Following the example of different authors, [30,31] we calculated
the [Cu/ZnSOD / (catalase + GPx)] activity ratio as the best index to
explain the chronic oxidative stress found in DS cells (Fig. 7). As expect-
ed, a signiﬁcant increase in this ratio was found in DS fetus ﬁbroblasts,lasts (C). (A) mRNA levels for SOD1 (the gene that codiﬁes for Cu/ZnSOD), determined by
CR (right). (B) Cu/ZnSOD andMnSOD protein levels analyzed byWestern blot, a represen-
raph bars showmean ± SD of a total of three experiments. Statistically signiﬁcant differ-
Fig. 5. Analysis of H2O2 detoxifying enzymes. (A) mRNA levels of CAT gene (left) andmRNA levels of GPX1 gene (right). (B) Determination of catalase and GPx1 protein levels byWestern
blot, a representative experiment. (C) Quantiﬁcation of Western blot of catalase (left) and GPx (right). Graph bars show mean ± SD of a total of three experiments.
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oxidant defenses takes place.
3.5. Rcan1 protein levels in Down Syndrome ﬁbroblasts
Down Syndrome critical region gene 1, also known as DSCR1 or
Rcan1 is present in chromosome 21. Its gene product interacts with cal-
cineurin A and inhibits calcineurin-dependent signaling pathways of
genetic transcription. Numerous reports consistently underscore the
low incidence of solid tumors in DS patients [32–35]. It has been pro-
posed that this is due to the increased expression of RCAN1 [36]. This
gene encodes a protein that is able to suppress the vascular endothelial
growth factor (VEGF) [37–42], thereby decreasing cell proliferation. The
purpose was to show a parallelism between the previously reported
high expression of Rcan1, with oxidative stress parameters and low
proliferative capacity in a cellular model during early development in
human Down Syndrome ﬁbroblasts.
Over-expression of RCAN1 has been reported in ﬁbroblasts and
in neurons from adult DS patients [36]. Fig. 8 shows that an over-expression of Rcan1 took place in ﬁbroblasts from fetal DS. It is known
that Rcan1 induces a decrease in proliferation of several cell lines by
the repression of different transcription factors and a decrease in synap-
tic development and activity [36,37]. Our results show that in early fetal
development, and not only in brain developmental cell lines, the ex-
pression of Rcan1 is increased, in keeping with an increase in oxidative
stress parameters and attrition of telomeres. This suggests an involve-
ment in the impairment of DS fetus ﬁbroblast proliferation.
4. Discussion
Different regulators of the proliferative cell capabilitywere decreased
in the cell model we studied. These changes impaired proliferation of
DS ﬁbroblasts when compared with control ﬁbroblasts from fetuses
(Fig. 1A). Indeed, the telomere length of ﬁbroblasts, a well-knownmark-
er of the proliferative cell potential, was signiﬁcantly shorter than its
control counterpart (Fig. 1B), suggesting that attrition of the telomeres
had a possible causative role in the decreased proliferative capability of
these cells. Varizi et al. [43] showed increased age-dependent telomere
Fig. 6. Analysis of antioxidant enzyme activities in Down Syndrome (DS) and control ﬁbroblasts (C). (A) Cu/ZnSOD activity and (B) MnSOD activity evaluated using the Superoxide Dis-
mutase Assay kit (Cayman, Ann Arbor,MI, USA) as describe in theMaterial andmethods section. (C) Catalase activitywas analyzed spectrophotometricallymeasuring the formation of the
purpald-formaldehyde adduct at 540 nm. (D)Glutathioneperoxidase activity determined by the glutathioneperoxidase assay kit (Cayman, AnnArbor,MI, USA) as describe in theMaterial
and methods section. All measurements were made in three ﬁbroblast cell lines from Down Syndrome patients and three control cell lines. Results are represented as mean (±SD).
Statistically signiﬁcant differences (p b 0.05) compared with the control value.
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control cells. Our TL results in embryonic DS human ﬁbroblasts correlat-
ed with the decrease in the length of telomeres found in hematopoietic
progenitor cells from DS fetuses [44].
Von Zglinicki [45] demonstrated that oxidative stress is a major
cause of telomere attrition. In different pathological situations, like
Fanconi anemia, a similar correlation was found between oxidative
stress, TL, and proliferative impairment [46]. Previous results have
shown impaired proliferation in ﬁbroblasts from adult DS patients
when compared with healthy individuals [10,47]. Kimura et al. [31]
used ﬁbroblasts from established cell lines from a repository of both
child and adult male DS patients and showed an initial impairment of
cell proliferation, but normal population doublings and lack of correla-
tionwith the TL. However, herewe show that, even in ﬁbroblasts obtain-
ed from DS fetuses, the proliferation rate is signiﬁcantly lower than inFig. 7. Ratio between the anti-oxidant enzyme activities. Cu/ZnSOD activity units
(superoxide detoxifying enzyme) divided by the decrease in catalase and GPx activities
(H2O2 detoxifying enzyme). Statistically signiﬁcant differences (p b 0.05) compared
with the control value.control cell lines, suggesting that the impaired proliferative capability
is a very early event in DS and not just a consequence of a chronic phys-
iopathologicalmechanism. A higher number of DS samples and their re-
spectivematched controlswould probably allow a statistical correlationFig. 8. (A) A representative experiment is shown for the determination of Rcan1 protein
levels by Western blot, using ﬁbroblasts 24 h after culture, from four different controls and
four different patients. (B) Quantiﬁcation of Western blot of Rcan1. Graph bars show
mean ± SD of a total of three experiments. Statistically signiﬁcant differences (p b 0.05)
compared with the control value.
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DS fetuses. This probably could clarify this clear tendency shown here
where cell lines from DS patients show shorter telomeres and lower
proliferation rate.
Trisomy 21 has long been known as a redox imbalance-related dis-
ease. The over-expression of copper–zinc superoxide dismutase (SOD1),
located in chromosome 21, is a landmark of the disease. The in vivo
pro-oxidant state in DS patients remains a conspicuous observation
both in vivo and in vitro [4–8,10]. However, the exact source of this oxi-
dative stress remains elusive, although mitochondria are obvious, and
one of the main candidate sources. In fact, we have previously described
considerable morphological, metabolic, and DNA changes in mitochon-
dria inDS (for a review see Pallardó et al.) [48] and other authors [49–51].
As previously underscored a number of reports have emphasized the
importance of the imbalance in the [Cu/ZnSOD / (catalase + GPx)] ac-
tivity in DS [9,10] and here, we show a similar imbalance in our DS cell
model ﬁbroblasts from human fetuses. Indeed, a considerable change in
the mRNA of SOD1 (Fig. 4A) expression and a pronounced increase in
the protein levels for Cu/ZnSOD (Fig. 4B and C) were found. These re-
sults correlated with the increased activity of Cu/ZnSOD (Fig. 6A). On
the other hand, a signiﬁcant decrease in the GPX gene expression, pro-
tein levels, and activity was also detected (Fig. 5). However, no changes
were found in catalase expression (Fig. 5). The variations in the gene
expression and protein levels produced a considerable impact in
the enzymatic activities of the antioxidant enzymes. Thus, whenwe cal-
culated the [Cu/ZnSOD / (catalase + GPx)] activity ratio (Fig. 7) it was
signiﬁcantly increased in ﬁbroblasts from DS fetuses when compared
with their control counterparts. We suggest that this imbalance in the
[Cu/ZnSOD / (catalase + GPx)] activity ratio gives rise to an oxidative
stress, producing high levels of hydrogen peroxide (Fig. 1C).
In keepingwith this, the analysis of theGSSG/GSH ratio, a recognized
marker of oxidative stress, showed a signiﬁcant increase (Fig. 1D). In
addition, the levels of oxidized proteins (Fig. 2B) in ﬁbroblasts from
DSwere higher than in control cells demonstrating that a clear oxidative
stress in these cells took place.
But the glutathione system is not the only antioxidant mechanism
that is affected. Our results showed that the glutathionylated proteins
were increased in DS ﬁbroblasts (Fig. 2A). Although oxidative stress
can contribute to this increase in glutathionylated proteins, the de-
toxifying systems involved in the de-glutathionylation of the oxi-
dized proteins may be affected. Fig. 3 shows that the thioredoxin
and glutaredoxin systems were also decreased in DS fetal ﬁbroblasts.
Results showed that both the TXN1 gene expression and the protein
levels were markedly decreased (Fig. 3A and C). Glutaredoxin 1 gene
expression and the protein levels were also decreased although to a
lesser extent (Fig. 3B and D). Thus, a distorted antioxidant scenario
emerges in cells from DS fetuses. The decrease in the gene expression
and protein levels of the glutaredoxin and thioredoxin systems partially
explains the increase in glutathionylated proteins. It has been previously
reported [52] that a decrease in the glutaredoxin system impairs
mitochondrial activity due to the increase of glutathionylated proteins
of the electronic transport chain.
In this preliminary study we describe for the ﬁrst time the contribu-
tion of thioredoxin and glutaredoxin systems to the imbalance of the
antioxidant system in DS, that explains, at least in part, the increased
levels of different free radical species in DS and the increase in oxidized
proteins. Trx1 has been described as one of the most important antiox-
idant enzymes. Furthermore, its down-regulation produces cell prolifer-
ation inhibition due to its importance in DNA synthesis [53], thus, it
contributes to the defects in the antioxidant shield and also to the low
proliferation capability of DS ﬁbroblasts.
Numerous reports consistently underscore the low incidence of solid
tumors in DS patients [32–35]. It has been proposed that this is due to
the increased expression of the Down Syndrome candidate region-1
(Dscr1/RCAN1) that is located in chromosome 21 [36]. This gene en-
codes a protein that is able to suppress the vascular endothelial growthfactor (VEGF) [37–42], thereby decreasing cell proliferation. Recently,
Dean Nižetić and Júrgen Groet wrote an impressive and challenging re-
view on this matter [54].
Baek et al. [55] proposed the calcineurin signaling pathway and its
regulators DSCR1 andDYRK1A as themechanism for the reduced cancer
incidence in DS. Fig. 1A shows impairment in cell proliferation in ﬁbro-
blasts from fetal DS individuals. We determinate the protein levels of
Rcan1 in order to explain this early decrease in the proliferative capabil-
ity of those cell lines from DS fetuses. As previously reported in other
cell types from DS patients [56,57], the expression of the different iso-
forms of Rcan1 detected by the antibody we used (a synthetic peptide
corresponding to amino acids 235–252 of human Rcan1) was increased
in ﬁbroblasts fromDS fetuses (Fig. 8). Ermark and Davies [58] suggested
that a prolonged elevation of RCAN1-1L levels, one of the isoforms of
RCAN1, is associated with the type of neurodegeneration observed in
several diseases, including Alzheimer's disease and DS. Here we show
that even in a very early step of human development (fetal ﬁbroblasts)
these changes are present in DS. Rcan1 is also involved in the regulation
of oxidative stress, at least in neurons [59]. Interestingly, the altered ex-
pression of nebula, the RCAN1 homologue of Drosophila melanogaster,
caused severe learning defects [60].
In addition to themitochondrial localization of nebula, its altered ex-
pression caused the increase of ROS levels andmitochondria number as
well as the reduction of ATP levels andmitochondrial DNA content [61].
The oxidative damage by H2O2 was lessened in primary neurons from
Rcan1−/− mouse [56]. Moreover, the sensitivity to oxidative stress
was increased when RCAN1-1Swas overexpressed [56].
Our preliminary results clearly indicate that the alteration of not
only SOD1 gene expression and Cu/ZnSOD protein levels, but also differ-
ent antioxidant enzymes, such as thioredoxin 1, contributes to the poor
proliferative capability of tissues in DS mediated by telomeric attrition,
and the increased expression of Rcan1, which partially explains the
progeroid phenotype of the patients.
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